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Background: Oxidative stress in primary aldosteronism (PA) is thought to worsen aldosterone-induced damage by activating proin-
flammatory processes. Therefore, we investigated whether inflammatory markers associated with oxidative stress is increased with 
negative impacts on heart function as evaluated by echocardiography in patients with PA. 
Methods: Thirty-two subjects (mean age, 50.3±11.0 years; 14 males, 18 females) whose aldosterone-renin ratio was more than 30 
among patients who visited Severance Hospital since 2010 were enrolled. Interleukin-1β (IL-1β), IL-6, IL-8, monocyte chemoattrac-
tant protein 1, tumor necrosis factor α (TNF-α), and matrix metalloproteinase 2 (MMP-2), and MMP-9 were measured. All patients 
underwent adrenal venous sampling with complete access to both adrenal veins.
Results: Only MMP-2 level was significantly higher in the aldosterone-producing adenoma (APA) group than in the bilateral adre-
nal hyperplasia (BAH). Patients with APA had significantly higher left ventricular (LV) mass and A velocity, compared to those with 
BAH. IL-1β was positively correlated with left atrial volume index. Both TNF-α and MMP-2 also had positive linear correlation 
with A velocity. Furthermore, MMP-9 showed a positive correlation with LV mass, whereas it was negatively correlated with LV 
end-systolic diameter. 
Conclusion: These results suggest the possibility that some of inflammatory markers related to oxidative stress may be involved in 
developing diastolic dysfunction accompanied by LV hypertrophy in PA. Further investigations are needed to clarify the role of oxi-
dative stress in the course of cardiac remodeling.
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INTRODUCTION
Primary aldosteronism (PA) is the most common and curable 
form of secondary hypertension (HTN) [1]. According to previ-
ous reports, the prevalence of PA was thought to be less than 1% 
of patients with mild to moderate essential HTN [2]. However, 
it has recently been estimated that PA is much more prevalent 
than previously believed, accounting for as many as 20% of pa-
tients with HTN [3]. It is mainly caused by autonomous aldoste-
rone production from a unilateral aldosterone-producing adeno-
ma (APA) or bilateral adrenal hyperplasia (BAH). Distinguish-
ing APA from BAH is important because effective treatment 
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differs according to subtypes [2].
Increasing evidence has shown that patients with PA experi-
ence more cardiovascular events related to blood pressure-inde-
pendent effects due to the excess of aldosterone itself, compared 
to those with essential HTN [4,5]. Moreover, prolonged elevat-
ed aldosterone levels can contribute to the development and 
progression of stroke, myocardial infarction, atrial fibrillation 
[4], and chronic kidney disease by inducing renal damage [6]. 
Some researchers have performed studies using echocardiogra-
phy [7] or cardiac magnetic resonance imaging [5] to evaluate 
clinical impact of PA. These deleterious effects on target organ 
damage appear to be involved with variable aldosterone-medi-
ated mechanisms including vascular inflammation [8] and the 
immune system [9], but the exact mechanism has not been fully 
clarified. 
Oxidative stress, which leads to endothelial dysfunction and 
organ damage [10], is thought to worsen aldosterone-induced 
damage by activating proinflammatory process. Zia et al. [10] 
stated that oxidative stress upregulates redox-sensitive nuclear 
transcription factor-κB and a proinflammatory gene cascade, 
such as tumor necrosis factor α (TNF-α) and monocyte che-
moattractant protein 1 (MCP-1). Petramala et al. [11] demon-
strated that patients with PA showed increased nicotinamide ad-
enine dinucleotide phosphate (NADPH) oxidase plasma levels 
and urinary isoprostanes than those with essential HTN. In ad-
dition, Stehr et al. [12] found that malondialdehyde as an oxida-
tive stress marker and amino terminal propeptides of type I 
known as a myocardial collagen deposition marker were signifi-
cantly higher in PA, compared to the essential HTN. Mean-
while, according to one study, antioxidant N-acetylcysteine pro-
tects pancreatic β-cells against aldosterone-induced oxidative 
stress and apoptosis in vivo and in vitro [13]. 
Given this background, we investigated the relationships be-
tween variable inflammatory markers associated with oxidative 
stress and echocardiographic parameters in patients with PA. 
Moreover, as APA usually shows higher aldosterone levels than 
BAH, we hypothesized that cardiac structure or functional 
changes due to adverse aldosterone-induced oxidative stress in 
APA may become more aggravated than those in BAH. 
METHODS
Study participants
Thirty-two patients with PA were enrolled among those who 
visited the HTN clinic at Severance Hospital from November 
2010 to September 2012. The inclusion criteria were as follows: 
subjects whose aldosterone-renin ratio (ARR) was more than 
30; who were confirmed with PA through saline loading test and 
adrenal venous sampling (AVS); for whom blood samples for 
the measurement of inflammatory markers were obtained. The 
patients included 14 males and 18 females, and their mean age 
was 50.3±11.0 years. A positive result was defined as post-
saline loading plasma aldosterone concentration (PAC) over 8.5 
ng/dL [14]. The protocol was approved by the Ethics Commit-
tee of the Yonsei University College of Medicine, and all partic-
ipants provided written consent (IRB No. 4-2014-0237). All in-
vestigations were performed in accordance with the principles 
of the Declaration of Helsinki. 
Subtype classification
To classify accurately subtypes of PA, adrenal computed tomog-
raphy (CT) was performed in three phases before AVS in all pa-
tients, with a 64-channel multiple detector CT scanner (Discov-
ery CT750HD, GE Healthcare, Milwaukee, WI, USA). The CT 
protocol was the same as previously described [15]. However, 
CT has the potential to be misleading by demonstrating unilat-
eral nodules in some patients with bilateral disease [2], and 
therefore AVS was also conducted to determine whether the site 
of aldosterone hypersecretion was unilateral or bilateral. 
According to a previous study [15] in which we found that C-
arm CT can enhance confidence of right adrenal vein catheter-
ization during AVS, we performed AVS using the same proto-
col. All patients underwent C-arm CT (Axiom Artis dTA, Sie-
mens, Erlangen, Germany) assisted sequential bilateral AVS 
with 100% successful access to both adrenal veins during con-
tinuous intravenous infusion of tetracosactide (Synacthen, 
Dalim Biotech, Hwaseong, Korea). Blood sampling was con-
ducted when C-arm CT images revealed proper catheter posi-
tion. Venous samples were obtained at least 30 minutes after 
initiation of intravenous tetracosactide administration. Adequate 
catheterization in AVS was defined as a cortisol ratio in adrenal 
vein and inferior vena cava blood samples equal to or more than 
3:1. In addition, when the adrenal venous blood cortisol-correct-
ed aldosterone ratio was greater than 2.6 after tetracosactide 
stimulation, a unilateral lesion was considered to be present on 
the high-value side [14]. 
Analysis for inflammatory markers associated with 
oxidative stress
Blood samples for the measurement of inflammatory markers 
related to oxidative stress were collected from all patients. The 
concentrations of interleukin-1β (IL-1β), IL-6, IL-8, MCP-1, 
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and TNF-α were measured using a Human Cytokine Magnetic 
kit (#HCYTOMAG-60K, Millipore, Billerica, MA, USA). As-
says for matrix metalloproteinase 2 (MMP-2) and MMP-9 were 
performed using the Human Cardiovascular Disease Magnetic 
Bead Panel (#HCVD3MAG-67K, Millipore) according to the 
manufacturer’s protocol. 
Assessment of cardiac structure and function
Echocardiography was performed in 23 subjects (71.9%). Com-
prehensive echocardiographic assessment was conducted by 
three experienced sonographers who had no knowledge of the 
clinical data using commercially available ultrasound systems 
(Sonos 5500, Philips Medical Systems, Andover, MA, USA; or 
Vivid Seven, GE Vingmed Ultrasound, Horten, Norway). All 
echocardiographic parameters were measured according to the 
recommendations of the American Society of Echocardiogra-
phy [16]. Images were obtained in the parasternal (long and 
short axis) and apical views. The following parameters were 
evaluated: left ventricular end-diastolic diameter (LVEDD, 
mm), left ventricular end-systolic diameter (LVESD, mm), in-
terventricular septum diameter (IVSd, mm) at end-diastole, left 
ventricular (LV) posterior wall diameter (PWd, mm) at end-di-
astole, and LV mass (g). LV mass was indexed for body surface 
area (left ventricular mass index [LVMI]). The left atrial volume 
index (LAVI) was calculated as the LA volume divided by body 
surface area. Left ventricular ejection fraction (LVEF) was cal-
culated according to the biplane Simpson’s method and apical 
four-and two-chamber views [17]. Relative wall thickness 
(RWT) was defined as 2×PWd divided by LVEDD. Early and 
late mitral ﬂow velocities (E and A, m/sec) and deceleration 
time (DT) of E velocity (msec) were measured using the pulsed 
wave Doppler method by placing a sample volume at the mitral 
valve leaﬂet tips. In addition, early diastolic mitral annular ve-
locity (E’, m/sec) was measured at the septal corner of the mi-
tral annulus using a tissue Doppler image in the apical four-
chamber view. We then calculated the E/A and E/E’ ratios, 
which mainly reflect diastolic function. The echocardiographic 
parameters were divided into two categories: structural abnor-
mality and diastolic function. LVEF, LVEDD, LVESD, IVSd, 
PWd, LV mass, LVMI, LAVI, and RWT indicate structural ab-
normality, meanwhile E and A velocities, DT, E/A and E/E’ ra-
tios were regarded as representative factors related to diastolic 
function.
Statistical analysis
Statistical analyses were conducted using PASW version 21.0 
(IBM Co., Armonk, NY, USA) and SAS version 9.2 (SAS Inc., 
Cary, NC, USA). Due to the small sample of patients, data were 
analyzed by nonparametric tests. The Mann-Whitney U test was 
used to compare differences in continuous variables between 
APA and BAH. Moreover, the Spearman partial correlation ad-
justed for age and sex was used to examine the relationships be-
tween inflammatory markers associated with oxidative stress 
and echocardiographic parameters. P values <0.05 were con-
sidered statistically significant. 
RESULTS
The baseline characteristics of all patients are presented in Table 
1. As noted earlier, females accounted for 56.3% of sample in 
this study. Mean HTN duration was approximately 8.0 years, 
and mean blood pressure was 149 over 92 mm Hg. In addition, 
mean ARR level was about 251. PAC level after the saline load-
ing test was approximately 16.5 ng/dL.
Differences in inflammatory markers associated with 
oxidative stress and aldosterone levels between APA and 
BAH
Table 2 demonstrates differences in inflammatory markers re-
lated to oxidative stress and hormone levels between APA and 




Body mass index, kg/m2 25.5±4.2
HTN duration, yr 8.0±7.3
History of previous vascular diseasesa 4
Systolic blood pressure, mm Hg 149.1±19.7
Diastolic blood pressure, mm Hg 91.5±12.6
Heart rate, beat/min 78.6±21.9




PAC after saline loading test, ng/dL 16.5±13.1
Values are expressed as mean±SD.
HTN, hypertension; PAC, plasma aldosterone concentration; PRA, 
plasma renin activity; ARR, aldosterone-renin ratio. 
aPrevious vascular diseases included angina pectoris, myocardial infarc-
tion, stroke or atrial fibrillation.
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BAH patients. In this study, the number of APA patients was 
similar to that of BAH patients (43.7% and 56.3%, respective-
ly), and no significant differences in blood pressure and heart 
rate between the two groups were found. As expected, there 
were significant differences in both serum potassium (3.3 
mmol/L vs. 3.9 mmol/L) and PAC (25.9 ng/dL vs. 20.7 ng/dL) 
between APA and BAH; ARR was significantly higher in the 
former than in the latter (163.3 vs. 68.6). In terms of inflamma-
tory markers associated with oxidative stress, the APA group 
showed significantly higher MMP-2 levels than the BAH group 
(86.8 ng/mL vs. 71.5 ng/mL); however, there were no differenc-
es in other cytokine levels between the two groups. We also 
found a linear relationship between MMP-2 levels and plasma 
aldosterone level (R=0.448, P=0.010) (Fig. 1).
Differences in echocardiographic parameters between 
APA and BAH
Differences in echocardiographic parameters between APA and 
BAH patients are reported in Table 3. Some of parameters 
showed different values between APA and BAH groups. Re-
garding parameters describing structural abnormalities of the 
Table 2. Differences in Inflammatory Markers Associated with Oxidative Stress and Aldosterone Levels between Patients with Aldoste-
rone-Producing Adenoma and Bilateral Adrenal Hyperplasia
Variable APA (n=14) BAH (n=18) P value
Age, yr 51.5 (29.0–70.0) 54.0 (27.0–64.0) 0.909
Systolic blood pressure, mm Hg 156.0 (122.0–195.0) 141.5 (119.0–200.0) 0.200
Diastolic blood pressure, mm Hg 90.0 (65.0–124.0) 88.5 (80.0–110.0) 0.733
Heart rate, beat/min 68.0 (60.0–75.0) 81.5 (57.0–93.0) 0.061
Serum potassium, mmol/L 3.3 (2.4–4.4) 3.9 (2.9–4.6) 0.006
PAC, ng/dL 25.9 (13.5–82.8) 20.7 (13.5–62.3) 0.040
PRA, ng/mL/hr 0.1 (0.0–1.0) 0.3 (0.0–0.6) 0.188
ARR 163.3 (45.9–1,655.3) 68.6 (28.9–1,053.8) 0.006
PAC after saline loading test, ng/dL 20.4 (10.8–67.4) 8.1 (5.4–21.6) <0.001
IL-1β, pg/mL 0.4 (0.1–12.5) 0.3 (0.1–1.1) 0.201
IL-6, pg/mL 1.6 (0.2–73.7) 0.6 (0.3–5.8) 0.217
IL-8, pg/mL 22.4 (5.9–773.0) 34.2 (4.8–262.0) 0.761
MCP-1, pg/mL 384.5 (85.1–811.0) 378.5 (76.1–770.0) 0.970
TNF-α, pg/mL 9.3 (2.5–64.6) 8.0 (2.8–18.9) 0.287
MMP-2, ng/mL 86.8 (57.8–122.0) 71.5 (52.4–121.0) 0.028
MMP-9, ng/mL 121.0 (31.1–839.0) 166.5 (38.5–902.0) 0.323
Values are expressed as median (range). The Mann-Whitney U test was used to compare differences in continuous variables between APA and BAH.
APA, aldosterone-producing adenoma; BAH, bilateral adrenal hyperplasia; PAC, plasma aldosterone concentration; PRA, plasma renin activity; ARR, 
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Fig. 1. Linear correlation between matrix metalloproteinase 2 
(MMP-2) and aldosterone levels. In the current study, there was a 
significant linear relationship between MMP-2 and plasma aldoste-
rone levels in patients with primary aldosteronism (R=0.448, 
P=0.010). The Spearman correlation was used to evaluate the lin-
ear relationship between MMP-2 and aldosterone levels. APA, al-
dosterone-producing adenoma; BAH, bilateral adrenal hyperplasia. 
APA
BAH
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heart, patients with APA had significantly higher LV mass and 
LVMI values compared to BAH, even though there was no sig-
nificant difference in RWT between the two groups. LVEF, 
LVEDD, LVESD, IVSd, and PWd of the two groups were simi-
lar. Moreover, there were no differences in parameters for dia-
stolic function such as E velocity, DT, or E/E’ ratio between the 
two groups except for A velocity, which was significantly higher 
in APA than that in BAH (P=0.047).
Association between inflammatory markers associated 
with oxidative stress and echocardiographic parameters
As shown in Table 4, we also evaluated whether the linear rela-
tionships were present between each level of inflammatory 
markers related to oxidative stress and echocardiographic pa-
rameters after adjustments for age and sex, because circulating 
cytokine levels can be modified by age and sex. IL-1β was posi-
tively correlated with LAVI, which is a structural factor reflect-
ing diastolic dysfunction (R=0.694, P=0.018). IL-6 also had a 
positive linear correlation with E velocity (R=0.680, P=0.011). 
Table 3. Differences in Echocardiographic Parameters between Patients with Aldosterone-producing Adenoma and Bilateral Adrenal 
Hyperplasia
Parameter APA (n=8) BAH (n=15) P value
Parameters for structural abnormality
   LVEF, % 68.5 (61.0–76.0) 71.0 (61.0–76.0) 0.112
   LVEDD, mm 48.0 (44.0–53.0) 50.0 (43.0–57.0) 0.516
   LVESD, mm 30.5 (27.0–36.0) 30.0 (26.0–36.0) 0.795
   IVSd, mm 12.0 (8.0–13.0) 11.0 (8.0–20.0) 0.265
   PWd, mm 11.0 (7.0–14.0) 11.0 (7.0–16.0) 0.578
   LV mass, g 234.6 (187.5–259.6) 174.5 (133.6–294.4) 0.034
   LVMI, g/m2 127.3 (101.9–153.6) 99.8 (74.7–136.2) 0.043
   LAVI, mL/m2 38.7 (20.6–54.0) 30.2 (22.1–50.4) 0.029
   RWT 0.45 (0.32–0.58) 0.44 (0.27–0.70) 0.561
Parameters for diastolic function
   E velocity, m/sec 0.8 (0.5–1.0) 0.7 (0.4–1.0) 0.260
   A velocity, m/sec 0.69 (0.72–1.11) 0.65 (0.47–0.84) 0.047
   E/A ratio 1.0 (0.7–1.4) 1.2 (0.5–2.0) 0.458
   Deceleration time, msec 181.0 (141.0–237.0) 194.0 (151.0–260.0) 0.183
   E’, m/sec 0.07 (0.04–0.11) 0.06 (0.03–0.11) 0.945
   E/E’ ratio 12.3 (6.8–20.0) 10.5 (6.0–20.0) 0.516
Values are expressed as median (range). The Mann-Whitney U test was used to compare differences in continuous variables between APA and BAH.
APA, aldosterone-producing adenoma; BAH, bilateral adrenal hyperplasia; LVEF, left ventricular ejection fraction; LVEDD, left ventricular end-diastol-
ic diameter; LVESD, left ventricular end-systolic diameter; IVSd, interventricular septum diameter; PWd, posterior wall diameter; LV, left ventricular; 
LVMI, left ventricular mass index; LAVI, left atrial volume index; RWT, relative wall thickness.
MCP-1 was positively correlated with A velocity (R=0.615, 
P=0.019), but showed a negative correlation with E’ velocity 
(R=–0.517, P=0.048). Both TNF-α and MMP-2 had positive 
linear correlations with A velocity (R=0.819, P<0.001; and 
R=0.751, P=0.002, respectively). MMP-9 was positively cor-
related with IVSd (R=0.538, P=0.047) as well as LV mass 
(R=0.553, P=0.040), whereas it showed a negative correlation 
with LVESD (R=–0.622, P=0.018). However, no significant 
linear relationships were detected between IL-8 and these echo-
cardiographic parameters. In addition, there were no linear cor-
relations between any of these inflammatory markers associated 
with oxidative stress and RWT in patients with PA. 
DISCUSSION
High aldosterone status was identified as an independent car-
diovascular risk factor [18]. Previous study has shown that car-
diovascular complications such as myocardial infarction, stroke, 
and sustained arrhythmia, are more prevalent in patients with 
Lim JS, et al.
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PA than in those with essential HTN, for which the odds ratio 
for overall cardiovascular events was 4.61 [19]. The increased 
risk of cardiovascular morbidity is associated with cardiac re-
modeling and LV changes that can be reversible through long-
term control with surgical or medical treatment for PA [20]. 
However, the mechanism underlying the adverse cardiovascular 
effects of aldosterone remains unclear.
Freel et al. [5] demonstrated that blood pressure-independent 
non-infarct myocardial fibrosis is frequent in those with PA. This 
phenomenon may be in part mediated through oxidative stress 
and inflammation. Oxidative stress markers such as NADPH 
oxidase plasma levels and urinary isoprostanes were decreased 
after laparoscopic adrenalectomy of APA. Furthermore, aldoste-
rone can lead to oxidative damage to the DNA and chromo-
somes [21] and promote the induction of reactive oxygen for-
mation via non-genomic effects [22]. Calo et al. [23] stated that 
oxidative stress and the associated signaling may be involved in 
causing oxidative damage to hot spot sequences in the Kir3.4 
gene, thereby contributing to the autonomy of aldosterone over-
production in PA. These results also support the theory that re-
active oxidant species play an essential role in the development 
of endothelial dysfunction and vascular remodeling of athero-
sclerotic processes, as well as progression of multi-organ dam-
age in high cardiovascular risk conditions [24]. Nevertheless, 
there are limited data regarding the influence of oxidative stress 
on cardiac structure and function in patients with PA, although a 
variety of studies have examined the effects of oxidative stress 
or inflammation markers on the heart disease [25]. 
Our findings indicate that some inflammatory markers associ-
ated with oxidative stress play an important role in developing 
diastolic dysfunction accompanied by concentric left ventricular 
hypertrophy (LVH), especially in patient with APA. In the cur-
rent study, only MMP-2 level was higher in patients with APA 
than in those with BAH. However, we found that LV mass and 
LVMI in the APA were significantly higher than in the BAH, al-
though there were no significant differences in blood pressure 
Table 4. Associations between Inflammatory Markers Associated with Oxidative Stress and Echocardiographic Parameters
Parameter
Correlation coefficient
IL-1β IL-6 IL-8 MCP-1 TNF-α MMP-2 MMP-9
Structural abnormality
   LVEF, % –0.162 0.023 –0.021 0.442 0.309 0.200 0.459
   LVEDD, mm 0.343 0.032 0.177 0.290 0.035 0.095 –0.313
   LVESD, mm 0.411 0.106 0.196 –0.083 –0.192 –0.099 –0.622a
   IVSd, mm 0.424 0.276 –0.060 –0.206 –0.008 –0.086 0.538a
   PWd, mm 0.099 –0.054 –0.315 –0.242 –0.205 –0.145 –0.061
   LV mass, g 0.386 0.478 –0.040 0.186 0.246 0.206 0.553a
   LVMI, g/m2 0.487 0.444 –0.101 –0.043 0.032 –0.037 0.329
   LAVI, mL/m2 0.694a 0.060 –0.001 –0.165 0.077 –0.115 0.040
   RWT –0.402 0.127 0.218 0.164 0.223 0.114 0.182
Function 
   E velocity, m/sec 0.587 0.680a 0.071 –0.214 –0.086 –0.160 0.265
   A velocity, m/sec –0.172 0.401 0.425 0.615a 0.819a 0.751a 0.502
   E/A ratio 0.520 0.402 0.029 –0.472 –0.436 –0.472 –0.133
   Deceleration time, msec 0.002 –0.100 0.053 0.446 0.120 0.267 –0.131
   E’, m/sec 0.335 0.127 –0.354 –0.517a –0.422 –0.371 –0.046
   E/E’ ratio 0.300 0.418 0.512 0.179 0.297 0.505 –0.031
The Spearman partial correlation adjusted for age and sex was used to examine the relationships between inflammatory markers associated with oxida-
tive stress and echocardiographic parameters.
IL, interleukin; MCP, monocyte chemoattractant protein; TNF-α, tumor necrosis factor α; MMP, matrix metalloproteinase; LVEF, left ventricular ejec-
tion fraction; LVEDD, left ventricular end-diastolic diameter; LVESD, left ventricular end-systolic diameter; IVSd, interventricular septum diameter; 
PWd, posterior wall diameter; LV, left ventricular; LVMI, left ventricular mass index; LAVI, left atrial volume index; RWT, relative wall thickness.
aP<0.05, after adjustment for age and sex.
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and heart rate between the two groups. Generally, when both 
LVMI and RWT are increased, concentric LVH can be defined 
[26]. Although the difference in RWT between the two groups 
was not significant, the pattern of concentric LVH was observed 
in all patients because the RWT was elevated in both groups, 
considering that the reference cut-off point for increased RWT 
is usually accepted to be 0.43 [26]. The results of our study are 
consistent with those of previous studies demonstrating that PA 
patients have frequent LVH and diastolic dysfunction [27]. Ex-
cess LVH appears to be an important factor increasing risk of 
cardiovascular events in patients with PA, compared with those 
with essential HTN [28].
Interestingly, LAVI was significantly elevated in APA patients 
compared to BAH. Since LA enlargement is attributable to sus-
tained elevation of LV filling pressure and atrial volume over-
load caused by diastolic dysfunction in hypertensive patients 
[29], LAVI is strongly associated with LV diastolic dysfunction, 
and this relationship is independent of age, sex, LVEF, and car-
diovascular risk score [30]. In this study, A velocity was also el-
evated in patients with APA compared to those with BAH, sug-
gesting the possibility of impact on diastolic function, although 
differences in E/A and E/E’ ratios between the two groups were 
not found. 
Moreover, a considerable number of inflammatory markers 
related to oxidative stress had linear correlations with echocar-
diographic parameters in patients with PA, even after adjust-
ments for age and sex. In this study, only IL-1β was positively 
correlated with LAVI (R=0.694, P=0.018), indicating that IL-
1β can worsen LV diastolic function in patients with PA. IL-1β, 
which is the main form of circulating IL-1, is known to play an 
important role in the amplification of tissue inflammatory re-
sponse; thereby, affecting the progression of atherosclerosis and 
cardiac remodeling [31]. IL-1β, as well as IL-6 and TNF- α, are 
usually increased in patients with chronic heart failure (HF), 
and can therefore be used to predict adverse outcome in these 
patients [31-33]. Thus, our results are consistent with those of 
previous studies related to IL-1β. In the case of IL-6, Fredj et al. 
[34] suggested that IL-6 signaling may be the key to promote 
cardiomyocyte hypertrophy, while Huang et al. [35] stated that 
IL-6 can tune myocardial remodeling through suppression of 
innate immune signals to prevent the catastrophic consequences 
of uncontrolled inﬂammation on cardiac geometry and function. 
However, we did not observe evidence that IL-6 has an influ-
ence on cardiac structure or function, although there was a posi-
tive linear correlation between IL-6 and E velocity in our study 
(R=0.680, P=0.011). We found no significant linear relation-
ships between IL-8 and any echocardiographic parameters. In 
this study, we did not measure IL-18 levels; however, Toldo et 
al. [33] demonstrated that IL-1 leads to a release of active IL-18 
in the experiments using mice, but not the induction of IL-6, in-
dicating the potential of IL-18 blockade as a novel therapeutic 
target of HF. 
The correlation coefficient between TNF-α and A velocity 
was high (R=0.819, P<0.001), but there were no relationships 
between TNF-α and other parameters. TNF-α is thought to have 
pleiotrophic effects on cardiovascular disease. Elevated TNF-α 
levels are positively correlated with the progression of HF, and 
have cytoprotective effects in myocardium of acute ischemic 
injury [36]. Furthermore, MCP-1 was positively correlated with 
A velocity (R=0.615, P=0.019), while it had a negative correla-
tion with E’ velocity (R=–0.517, P=0.048), which is relatively 
insensitive to change of preload in the presence of LV systolic 
dysfunction [37]. Thus, we speculated that MCP-1 also affects 
the development of functional abnormality in the diastolic 
phase. According to previous results described by Blasi et al. 
[6], renal expression levels of proinflammatory gene, such as 
MCP-1, IL-1β, or IL-6, were significantly increased following 
28 days of aldosterone administration, and this phenomenon 
was attenuated by eplerenone treatment. In addition, MCP-1 
contributes to the recruitment of monocytes to injury sites by 
interacting with chemokine receptor 2 expressed on the surface 
of monocytes, and IL-1β plays a role in enhancing the expres-
sion of adhesion molecules by immune cells through the inter-
action with IL-1β receptor [9]. 
In the current study, MMP-2 levels were significantly higher 
in the APA group than in the BAH group. We observed a linear 
relationship between MMP-2 and plasma aldosterone levels 
(R=0.448, P=0.010) (Fig. 1). The activities of MMP, which is 
known as a family of proteolytic enzymes, have been examined 
as candidate biomarkers or therapeutic targets for cardiovascular 
disease, including myocardial infarction and congestive HF [38]. 
MMP activation mediates myocardial remodeling in cardiac 
pathogenesis [38]. Hughes et al. [39] demonstrated that MMP-2 
localized in mitochondria-associated heart membrane could af-
fect mitochondria function by influencing endoplasmic reticu-
lum Ca2+ signaling. We also observed a positive linear correla-
tion between MMP-2 level and A velocity (R=0.751, P=0.002). 
Therefore, we speculate that MMP-2 can be an aggravating fac-
tor for the cardiac structure or diastolic function in the APA pa-
tients with higher aldosterone levels than BAH patients. In addi-
tion, MMP-9 was positively correlated with LV mass (R=0.553, 
P=0.040) and IVSd (R=0.538, P=0.047), whereas it showed a 
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negative correlation with LVESD (R=–0.622, P=0.018), sug-
gesting that MMP-9 may be associated with cardiac remodeling. 
According to Halade et al. [40], MMP-9 can serve as a proximal 
biomarker for cardiac remodeling and a distal biomarker for in-
flammation. Thus, in the future, more research is needed to ex-
plain the roles or interactions of these cytokines in the develop-
ment of adverse outcomes in patients with PA. 
To our knowledge, this is the first clinical study to analyze 
differences in inflammatory markers associated with oxidative 
stress according to subtypes of PA. Although previous research 
addressed increases in oxidative stress, such as NADPH oxidase 
plasma levels [22], malondialdehyde or amino terminal propep-
tides of type I [12] in patients with PA, they compared patients 
with PA and essential HTN. We further investigated cardiac 
structure and function with echocardiography in order to evalu-
ate whether aldosterone-induced oxidative stress has an impact 
on heart condition, detecting strong correlations between each 
marker and echocardiographic parameter in PA even after ad-
justments for age and sex. 
However, this study also has some limitations. First, this is 
cross-sectional study, and it is therefore difficult to infer causali-
ty. Secondly, the study sample was small. That may be why we 
could not reconfirm the linear relationship between inflamma-
tory markers such as MMP-2 and plasma aldosterone levels af-
ter the adjustment for confounding factors. Thirdly, this study 
had no control group matched to PA patients in age, sex, body 
mass index, HTN duration, blood pressure, smoking and so on. 
Fourthly, echocardiographic assessment was performed by three 
sonographers. So, there might be inter-individual variations 
among them. Finally, when blood sample volume is insufficient 
or circulating cytokine levels are low, analytical variation is 
likely. Hence, assessing the additional effects of inflammatory 
markers related to oxidative stress on adverse cardiovascular 
outcomes in patients with PA requires a large well-designed re-
search study with long-term follow-up. 
In summary, our results suggest that inflammatory markers 
associated with oxidative stress are involved in developing dia-
stolic dysfunction as well as LV hypertrophy in patients with 
PA. However, we have little explanation to fully answer the 
mechanism underlying the role of oxidative stress in PA, be-
cause the roles of some of these cytokines in the development 
of cardiovascular disease remain controversial. Nevertheless, 
aldosterone seems to promote the recruitment or activation of 
immune cells by several mechanisms [9]. For this reason, better 
understanding the mechanisms of aldosterone-induced target 
organ damage by enhanced oxidative stress may be a new ave-
nue for developing a promising therapeutic target for PA. Fur-
ther investigations are needed to clarify the role of oxidative 
stress in the course of cardiac remodeling.
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